Scientific programme

The scientific programme is structured around basic science, translational medicine and clinical sessions, given by some of the world’s top specialists. It also includes oral presentations of the best abstracts, the announcement of ECCO Fellowships and Grants and summary presentations of new ECCO Guidelines.  The focus of all sessions is clinical practice founded on science, with practical messages to take home.
Scientific sessions are held from Thursday, February 16 to Saturday, February 18, 2017. The congress registration fee includes access to all scientific sessions.

Final programme
(as of January 17, 2017)

Advancing knowledge, improving care

  • Plenary hall

    10:45-11:15 Top Tips for chairs (closed session)
    Laurence Egan, Galway, Ireland
    11:30-12:30  
    Industry sponsored satellite symposia 1a & 1b 
      12:45-12:50  1: Welcome
    Javier Gisbert, Madrid, Spain
      12:50-13:00   2: Opening
    Julián Panés, Barcelona, Spain
    13:00-14:30   
    Scientific session 1: Pathways of environmental and genetic factors in IBD
    Stephan Vavricka, Zurich, Switzerland
    Nynne Nyboe Andersen, Copenhagen, Denmark
      13:00-13:20   3: Nutrition and Food additives
    Charlie Lees, Edinburgh, United Kingdom
      13:20-13:30   4: OP001: Whole genome sequencing and imputation in Inflammatory Bowel Disease identifies 26 novel loci and offers therapeutically-relevant mechanistic insights

    Moutsianas, L.1
    , De Lange, K. 1, Luo, Y.1,2,3, Lee, J.4, Jostins, L.5, Lamb, C.6, Kennedy, N.7, Mansfield, J.8, Parkes, M.4, Barrett, J.1, Anderson, C.1, K Inflammatory Bowel Disease Genetics Consortium, U.9 
    1Wellcome Trust Sanger Institute, Human Genetics, Hinxton, Cambridge, United Kingdom, 2Broad Institute of Harvard and MIT, Program in Medical and Population Genetics, Cambridge, United States, 3Harvard Medical School, Division of Genetics and Rheumatology, Boston, United States, 4Addenbrooke's Hospital, Inflammatory Bowel Disease Research Group, Cambridge, United Kingdom, 5Wellcome Trust Centre for Human Genetics, Oxford, United Kingdom, 6Newcastle University, Newcastle upon Tyne, United Kingdom, 7University of Exeter, Precision Medicine Exeter, Exeter, United Kingdom, 8University of Newcastle, Human Genetics, Newcastle upon Tyne, United Kingdom, 9UK IBD Genetics Consortium, Various, United Kingdom
      13:30-13:50  
    5: Everyday poisons: Smoking, pollution, stress, sedentary lifestyle
    Stephan Vavricka, Zurich, Switzerland
      13:50-14:00   6: OP002: Epigenetic biomarkers to detect UC associated neoplasia: Results from phase I of the ENDCAP-C study

    Iqbal, T.1, Beggs, A.1, Taniere, P.2, Wallis, Y.3, Mehta, S.4, Magill, L.4, Deeks, J.4, Matthews, G.1, Morton, D.1, EndCAP-C Consort
    1University of Birmingham, Institute of Cancer & Genomic Sciences, Birmingham, United Kingdom, 2University Hospital Birmingham NHS Foundation Trust, Birmingham, United Kingdom, 3West Midlands Regional Genetics Centre, Birmingham, United Kingdom, 4University of Birmingham, Birmingham Clinical Trials Unit, Birmingham, United Kingdom
      14:00-14:10  7: OP003: Increased risk of acute arterial events in young patients with severely active Inflammatory Bowel Disease: A nationwide French cohort study

    Kirchgesner, J.1,2,
    Beaugerie, L.1, Carrat, F.3,4, Nyboe Andersen, N.5, Jess, T.5,6, Schwarzinger, M.7,8, For the BERENICE Study Gr
    1Saint-Antoine Hospital, AP-HP, Gastroenterology, Paris, France, 2INSERM, University Paris 06, UMR S 1136, Paris, France, 3Hopital Saint Antoine, Department of Public Health, Paris, France, 4INSERM, University Paris 06 , UMR S 1136 , Paris, France, 5Statens Serum Institute, Department of Epidemiology Research, Copenhagen, Denmark, 6Frederiksberg Hospital, Institute of Preventive Medicine, Frederiksberg, Denmark, 7INSERM, UMR 1137, Paris, France, 8THEN, Translational Health Economics Network, Paris, France
      14:10-14:30   8: Environmental factors as therapy (diet modification; EEN feeding)
    Pierre Ellul, Sliema, Malta 
    Arie Levine, Tel Aviv, Israel
    14:30-15:00 Coffee break 
    15:00-16:30 Scientific session 2: Evolving therapeutic algorithms in 2017
    Jane Andrews, Adelaide, Australia
    Jaroslaw Kierkus, Warsaw, Poland
      15:00-15:20 9: Placing new molecules in the treatment pathway
    Gerhard Rogler, Zurich, Switzerland
      15:20-15:30 10: OP004: Resetting of the mucosal T cell repertoire after hematopoietic stem cell transplantation in refractory Crohn's Disease

    Le Bourhis, L.1, Corraliza, A.2, Auzolle, C.1, Ricart, E.2, Hawkey, C.3, Lindsay, J.O.4, Clark, M.3, Rogler, G.5, Satsangui, J.6, Haller, D.7, Panes, J.2, Salas, A.2, Allez, M.1
    1Hôpital Saint-Louis INSERM, U1160 - Intestinal Immunity in Inflammation and Cancer, Paris, France, 2IDIBAPS, Hospital Clínic, Gastroenterology, Barcelona, Spain, Barcelona, Spain, 3University of Nottingham, Gastroenterology, Nottingham, United Kingdom, 4Barts and The London, Queen Mary University of London, Centre for Immunology, The Blizard Institute, London, United Kingdom, 5University Hospital  Zurich, Department of Gastroenterology and Hepatology, Zurich, Swaziland, 6Western General Hospital, Gastrointestinal Unit, Centre for Genomic and Experimental Medicine, Edinburgh, United Kingdom, 7Technical University Munich, Department of Nutrition and Immunology, Freising, Germany
      15:30-15:50 11: Maximising the bang for your buck: How to manage IBD on a minimum budget
    Peter Irving, London, United Kingdom
      15:50-16:00 12: OP005: The PROSIT cohort of infliximab biosimilar in IBD: A prolonged follow-up on the efficacy and safety across Italy

    Guidi, L.1, Fiorino, G.2, Variola, A.3, Manetti, N.4, Fries, W.5, Rizzuto, G.6, Bossa, F.7, Cappello, M.8, Biancone, L.9, D'Incà, R.10, Cantoro, L.11, Castiglione, F.12, Principi, M.13, Annunziata, M.L.14, Di Girolamo, M.15, Terpin, M.M.16, Cortelezzi, C.C.17, Costa, F.18, Amato, A.19, Di Sabatino, A.20, Saibeni, S.21, Meucci, G.22, Petruzzellis, C.23, Tari, R.24, Gugliemi, F.W.25, Armuzzi, A.26, Danese, S.2, Geccherle, A.3, Rogai, F.4, Ventra, A.5, Orlando, A.6, Andriulli, A.7, Scrivo, B.8, Troncone, E.9, Caccaro, R.10, Kohn, A.11, Nardone, O.12, Annese, V.27
    1Complesso Integrato Columbus, Fondazione Policlinico Gemelli Universita' Cattolica, Internal Medicine and Gastroenterology, Rome, Italy, 2Humanitas Research Hospital and University, Gastroenterology and IBD Center, Rozzano, Italy, 3Sacro Cuore Don Calabria Hospital, Gastroenterology and Hepatology, Negrar, Italy, 4AOU Careggi, DEA, Gastroenterology, Florence, Italy, 5University of Messina, Clinical Unit for Chronic Bowel Disorders, Messina, Italy, 6Riuniti Villa Sofia - Cervello Hospital, Internal Medicine 2, Palermo, Italy, 7IRCCS-CSS Hospital, Gastroenterology, San Giovanni Rotondo, Italy, 8University Hospital, Gastroenterology, Palermo, Italy, 9Tor Vergata, Gastroenterology, Roma, Italy, 10University of Padova, Gastroenterology, Padova, Italy, 11S. Camillo-Forlanini Hospital, Gastroenterology, Rome, Italy, 12Federico II University, Gastroenterology, Naples, Italy, 13University Bari, Gastroenterology, Bari, Italy, 14IRCCS Policlinico, Gastroenterology & Digestive Endoscopy Unit, San Donato, Milano, Italy, 15University Hospital, Gastroenterology, Modena, Italy, 16AO Hospital, Gastroenterology and Endoscopy, Legnano, Italy, 17AOU di Circolo Fondazione Macchi, Gastroenterology, Varese, Italy, 18AOUP, Gastroenterology, Pisa, Italy, 19Ospedale Valduce, Gastroenterology, Como, Italy, 20S.Matteo Hospital Foundation, University of Pavia, First Department of Medicine, Pavia, Italy, 21ASST Rhodense, Gastroenterology Unit, Rho, Italy, 22S. Giuseppe Hospital, Gastroenterology, Milano, Italy, 23Poliambulanza Hospital, Gastroenterology and Digestive Endoscopy, Brescia, Italy, 24AOU Maggiore, Gastroenterology, Novara, Italy, 25S. Pellegrino Hospital, Gastroenterology, Trani, Italy, 26Complesso Integrato Columbus - Catholic University, Internal Medicine and Gastroenterology, Rome, Italy, 27Valiant Clinic, Gastroenterology, Dubai, United Arab Emirates
      16:00-16:10 13: OP006: Correlation of durability of response, serum trough concentrations and outcome parameters: Long-term follow-up of the Trough Concentration Adapted Infliximab Treatment (TAXIT) trial

    Pouillon, L.1, Ferrante, M.1, Van Assche, G.1, Rutgeerts, P.1, Noman, M.1, Vande Casteele, N.2, Gils, A.3, Vermeire, S.1
    1University Hospitals Leuven, Department of Gastroenterology and Hepatology, Leuven, Belgium, 2University of California San Diego, Department of Medicine, La Jolla, CA, United States, 3University of Leuven, Department of Pharmaceutical Sciences, Leuven, Belgium
      16:10-16:30 14: Personalised medicine: Dream or reality?
    Iris Dotan, Tel Aviv, Israel
    16:30-17:30 Scientific session 3: Vulnerable patients: 10 burning questions in IBD
    Pierre Michetti, Lausanne, Switzerland
    Triana Lobatón, Barcelona, Spain
      16:30-16:42 15: The child with IBD: Should anti-TNF be used as a mono-therapy in children (safety risk)? Who should (be allowed) to operate on the children in IBD?
    Dan Turner, Jerusalem, Israel
      16:42-16:54 16: Treating the pregnant woman with IBD:Should anti-TNF be stopped during pregnancy? Should Vedolizumab be stopped during pregnancy?
    Janneke van der Woude, Rotterdam, The Netherlands
      16:54-17:06 17: The elderly patient with IBD: Should Azathioprine ever be used in the elderly? Should the type of surgery be different in an elderly patient?
    Jean-Frédéric Colombel, New York, United States
      17:06-17:18 18: The use of IBD medicine in patients with cancer: Which treatment should be stopped when cancer is diagnosed? Which treatment to use in a patient with a prior diagnosis with cancer?
    Laurent Beaugerie, Paris, France
      17:18-17:30 19: The patient with psychological comorbidities: How to wean off opiates in the these patients? Is there any preference in drugs?
    Jane Andrews, Adelaide, Australia
    17:45-18:45
    Industry sponsored satellite symposia 2a & 2b
    17:45-18:45 Digital oral presentations (Sessions 1-5)
  • Plenary hall

    07:15-08:15 Industry sponsored satellite symposia 3a & 3b
    08:30-10:30 Scientific session 4: Clinical trials versus real life
    Janneke van der Woude, Rotterdam, The Netherlands
    Pascal Juillerat, Bern, Switzerland
      08:30-08:50 20: Trial endpoint vs. therapeutic objectives
    Filip Baert, Roeselare, Belgium
      08:50-09:00 21: OP007: A multi-centre double blind randomised placebo-controlled study of the use of rectal tacrolimus in the treatment of resistant ulcerative proctitis

    Lawrance, I.C.1,2, Baird, A.1, Lightowler, D.2, Radford-Smith, G.3, Andrews, J.M.4, Connor, S.5
    1University of Western Australia, Medicine and Pharmacology, Perth, Australia, 2Saint John of God Hospital, Centre for Inflammatory Bowel Diseases, Subiaco, Australia, 3University of Queensland School of Medicine, IBD Research Group, QIMR Berghofer Medical Research Institute, Brisbane, Australia, 4University of Adelaide, School of Medicine, Adelaide, Australia, 5University of NSW Medicine, South Western Sydney Clinical School, Sydney, Australia
      09:00-09:10 22: OP008: An innovative treatment for refractory perianal fistulas in Crohn’s Disease: Local micro reinjection of autologous fat and adipose derived stromal vascular fraction (ClinicalTrials.gov NCT02520843, Eudract : 2013-002602-31)

    Serrero, M.1, Philandrianos, C.2, Visee, C.3, Veran, J.2, Orsoni, P.3, Sabatier, F.2, Grimaud, J.-C.1
    1Hopital Nord, Gastroenterology, Marseille, France, 2Aix-Marseille, Marseille, France, 3Hopital Nord, Visceral Surgery, Marseille, France
      09:10-09:20 23: OP009: Long-term efficacy and safety of Cx601, allogeneic expanded adipose-derived mesenchymal stem cells, for complex perianal fistulas in Crohn’s Disease: 52-week results of a phase III randomised controlled trial

    Panés, J.1, García-Olmo, D.2, Van Assche, G.3, Colombel, J.F.4, Reinisch, W.5, Baumgart, D.C.6, Nachury, M.7, Ferrante, M.3, Kazemi-Shirazi, L.5, Grimaud, J.C.8, de la Portilla, F.9, Goldin, E.10, Richard, M.P.11, Diez, M.C.11, Danese, S.12
    1Hospital Clínic de Barcelona, Dept of Gastroenterology, Barcelona, Spain, 2Hospital U. Fundación Jiménez-Díaz, Madrid, Spain, 3University Hospitals Leuven, KU Leuven, Leuven, Belgium, 4Icahn School of Medicine at Mount Sinai, New York, United States, 5Medical University of Vienna, Vienna, Austria, 6Charité Medical School - Humboldt-University of Berlin, Berlin, Germany, 7CHU Lille, Lille, France, 8Hôpital Nord, Marseille, France, 9Hospital Virgen del Rocío, Sevilla, Spain, 10Sharee Zedek MC, Jerusalem, Israel, 11TiGenix, Madrid, Spain, 12Istituto Clinico Humanitas, Milano, Italy
      09:20-09:40 24: The long term efficacy outside clinical trials
    Stefan Schreiber, Kiel, Germany
      09:40-09:50 25: OP010: Long term efficacy and safety of Ustekinumab for Crohn’s Disease: Results from IM-UNITI long-term extension through 2 years

    Sandborn, W.1, Rutgeerts, P.2, Gasink, C.3, Jacobstein, D.3, Gao, L.-L.3, Johanns, J.3, Sands, B.4, Hanauer, S.B.5, Targan, S.6, Ghosh, S.7, Willem J.S., d.V.8, Colombel, J.-F.4, Feagan, B.G.9
    1University of California San Diego, La Jolla, United States, 2University Hospital, Gasthuisberg, Leuven, Belgium, 3Janssen Research & Development, LLC, Spring House, United States, 4Icahn School of Medicine at Mt Sinai, New York, United States, 5Northwestern University Feinberg School of Medicine, Chicago, United States, 6Cedars-Sinai Medical Center, Los Angeles, United States, 7University of Birmingham, Birmingham, United Kingdom, 8University of Stellenbosch, Stellenbosch, South Africa, 9Robarts Clinical Trials, Robarts Research Institute, Western University, London, Ont,, Canada
      09:50-10:00 26: OP011: Etrolizumab treatment leads to early improvement in symptoms and inflammatory biomarkers in anti-TNF-refractory patients in the open-label induction cohort of the phase 3 HICKORY study

    Peyrin-Biroulet, L.1, Feagan, B.G.2, Mansfield, J.3, Rubin, D.T.4, Arulmani, U.5, Maciuca, R.5, Tyrrell, H.6, Thommes, J.5, Tole, S.6
    1Université de Lorraine, Vandœuvre-lès-Nancy, France, 2University of Western Ontario, London, Canada, 3Newcastle University, Newcastle upon Tyne, United Kingdom, 4University of Chicago Medicine, Chicago, United States, 5Genentech, South San Francisco, United States, 6Roche, Welwyn Garden City, United Kingdom
      10:00-10:10 27: OP012: Perioperative use of vedolizumab is not associated with short-term postoperative infectious complications in patients with Ulcerative Colitis undergoing (procto)colectomy with ileal pouch-anal anastomosis

    Ferrante, M.1, Schils, N.1, de Buck van Overstraeten, A.2, Vermeire, S.1, Van Assche, G.1, Wolthuis, A.2, D'Hoore, A.2
    1University Hospitals Leuven, Department of Gastroenterology and Hepatology, Leuven, Belgium, 2University Hospitals Leuven, Department of Abdominal Surgery, Leuven, Belgium
      10:10-10:30 28: The long-term safety outside clinical trials
    Gert van Assche, Leuven, Belgium
    10:30-11:00 Coffee Break
    11:00-12:30 Scientific session 5: Managing bowel damage in IBD: Surgical or medical treatment?
    Antonino Spinelli, Milan, Italy
    Edyta Zagórowicz, Warsaw, Poland
      11:00-11:20 29: Are we truly changing disease course with current strategies?
    Yves Panis, Clichy, France
      11:20-11:30 30: OP013: Disease management and outcomes of patients with Crohn's Disease at high risk of recurrence. Results from PRACTICROHN study

    Iborra, M.1, Martín Arranz, M.D.2, Domènech, E.3, García, V.4, Gutiérrez, A.5, Barreiro-de Acosta, M.6, Cea-Calvo, L.7, Romero, C.7, Juliá, B.7
    1Servicio de Gastroenterologia, Hospital La Fe, Valencia, Spain, 2Hospital Universitario La Paz, Gastroenterology Unit, Madrid, Spain, 3Hospital Universitari Germans Trias i Pujol and CIBERehd, Gastroenterology Unit, Badalona, Spain, 4Hospital Universitario Reina Sofia, Unidad Clinica de Aparato Digestivo, Cordoba, Spain, 5Hospital General Universitario Alicante, Gastroenterology unit, Alicante, Spain, 6Complejo Hospitalario Universitario de Santiago, Gastroenterology Unit, Santiago de Compostela, Spain, 7MSD Spain, Medical Department, Madrid, Spain
      11:30-11:50 31: Combined approach for intestinal sparing in CD?
    Paulo Kotze, Curitiba, Brazil
      11:50-12:00 32: OP014: Histological remission is predictive of improved clinical outcomes in patients with Ulcerative Colitis: Results from the TOUCHSTONE OLE

    Sandborn, W.1, Feagan, B.2, D'Haens, G.3, Levesque, B.2, Pai, R.4, Hanauer, S.5, Wolf, D.6, Vermeire, S.7, Ghosh, S.8, Li, C.9, Penenberg, D.9, Aranda, R.9, Olson, A.9
    1University of California San Diego, San Diego, United States, 2Robarts Research, London, Canada, 3Academic Medical Center, Amsterdam, Netherlands, 4Mayo Clinic, Department of Laboratory Medicine and Pathology, Scottsdale, United States, 5Feinberg School of Medicine, Chicago, United States, 6Atlanta Gastroenterology Associates, Atlanta, United States, 7University of Leuven, Leuven, Belgium, 8University of Calgary, Calgary, Canada, 9Receptos, a wholly owned subsidiary of Celgene, San Diego, United States
      12:00-12:10 33: OP015: Cost-effectiveness of laparoscopic ileocecal resection versus infliximab treatment of terminal ileitis in Crohn’s Disease: THE LIR!C TRIAL

    de Groof, J.1,2
    , Bemelman, W.1, Eshuis, E.2, Gardenbroek, T.1, Bossuyt, P.3, Bosmans, J.4, van Dongen, H.4, van Wagensveld, B.5, Brink, M.6, Consten, E.7, Buskens, C.1, D'Haens, G.2, Stokkers, P.8, Ponsioen, C.2, LIR!C study gr
    1Academic Medical Center, Surgery, Amsterdam, Netherlands, 2Academic Medical Center, Gastroenterology, Amsterdam, Netherlands, 3Academic Medical Center, Epidemiology, Amsterdam, Netherlands, 4VU, Health Sciences, Amsterdam, Netherlands, 5OLVG West, Surgery, Amsterdam, Netherlands, 6Meander Medical Center, Gastroenterology, Amersfoort, Netherlands, 7Meander Medical Center, Surgery, Amersfoort, Netherlands, 8OLVG West, Gastroenterology, Amsterdam, Netherlands
      12:10-12:30 34: The ilorectal anastomosis in UC: Time for a comeback?
    Oded Zmora, Tel Aviv, Israel
    12:30-13:30 Lunch break & Guided poster session
    12:40-13:20
    Industry sponsored educational lunchtime satellite symposia LS1,LS2,LS3,LS4
    13:30-15:00 Scientific session 6: Intestinal inflammation - not always IBD
    Eugeni Domènech, Badalona, Spain
    Dror Shouval, Tel Aviv, Israel

    Carousel:
    Epidemiologist - Vito Annese, Florence, Italy
    Basic Science - Britta Siegmund, Berlin, Germany
    Pathologist - Roger Feakins, London, United Kingdom
    Physician - James Lindsay, London, United Kingdom
      13:30-13:50 35: Microscopic colitis
    Carousel
      13:50-14:00 36: OP016: Potential role of bile acid receptor FXR in microscopic colitis

    Palmela, C.
    1, Torres, J.1, Gomes de Sena, P.2, Costa Santos, M.P.1, Gouveia, C.1, Oliveira, M.H.2, M. P. Rodrigues, C.3, Cravo, M.1, Borralho, P.4,5
    1Hospital Beatriz Ângelo, Gastrenterology Department, Loures, Portugal, 2Hospital Beatriz Ângelo, Pathology Department, Loures, Portugal, 3Faculty of Pharmacy, Universidade de Lisboa, Research Institute for Medicines, Lisboa, Portugal, 4Hospital Cuf Descobertas, Pathology Department, Lisboa, Portugal, 5Universidade de Lisboa, Faculty of Medicine, Lisboa, Portugal
      14:00-14:20 37: IBDU
    Carousel
      14:20-14:30 38: OP017: Telemedicine enables a safe shift from examination room based care to personalised care for Inflammatory Bowel Disease: A pragmatic randomised multicenter trial with myIBDcoach

    de Jong, M.
    1,2, van der Meulen-de Jong, A.3, Romberg-Camps, M.4, Becx, M.5, Cilissen, M.1, Maljaars, J.3, van Bodegraven, A.4, Mahmmod, N.5, Markus, T.6, Hameeteman, W.1, Dijkstra, G.7, Masclee, A.1,2, Boonen, A.8,9, Jonkers, D.1,2, van Tubergen, A.8,9, Pierik, M.1,2
    1Maastricht University Medical Center (MUMC), Department of Internal Medicine, division of Gastroenterology and Hepatology, Maastricht, Netherlands, 2Maastricht University Medical Center (MUMC), NUTRIM – School for Nutrition and Translational Research in Metabolism, Maastricht, Netherlands, 3Leiden University Medical Centre, Department of Gastroenterology and Hepatology, Leiden, Netherlands, 4Zuyderland Medical Centre, Department of Gastroenterology and Hepatology, Sittard-Geleen, Netherlands, 5St. Antonius Hospital, Department of Gastroenterology and Hepatology, Nieuwegein, Netherlands, 6CCUVN, Woerden, Netherlands, 7University Medical Center Groningen, Department of Gastroenterology and Hepatology, Groningen, Netherlands, 8Maastricht University Medical Center (MUMC), Department of Internal Medicine, division of Rheumatology, Maastricht, Netherlands, 9Maastricht University Medical Center (MUMC), CAPHRI - School for Public Health and Primary Care, Maastricht, Netherlands
      14:30-14:40 39: OP018: Optimal anti-TNF stop week during pregnancy depends on anti-TNF type

    Kanis, S.
    , de Lima, A., van der Woude, C.
    Erasmus University Medical Center, Gastroenterology and Hepatology, Rotterdam, Netherlands
      14:40-15:00 40: Eosinophilic enteritis
    Carousel
    EITHER:
    15:00-15:40 Scientific session 7: ECCO Fellowship and Grants
    Britta Siegmund, Berlin, Germany
    Gionata Fiorino, Milan, Italy
    Plenary Hall, Ground Level, CCIB